期刊文献+

IL-17A在纤维化疾病中的研究进展 被引量:4

Progress on fibrotic diseases via IL-17A
下载PDF
导出
摘要 白细胞介素-17A (IL-17A)是一种具有多种生物学功能的细胞因子,参与多种疾病的发病机制,通常情况它被认为在炎症反应中起重要作用,它可以募集炎症细胞至疾病部位,可进一步调节炎症细胞分泌炎症介质等发挥抗炎作用,但近年来研究发现IL-17A在许多纤维化疾病中有促进组织纤维化的作用,本文主要从炎症及纤维化角度分析了IL-17A在相关疾病中的作用,提示以IL-17A为干预靶点有可能使患者受益。 Interleukin-17 A(IL-17 A) is a cytokine with a multi-biological function, which is involved in the pathogenesis of many diseases. Generally, it is considered to play an important role in the inflammatory response. It can recruit inflammatory cells to the site of the disease and further regulate the secretion of inflammatory mediators by inflammatory cells. However, in recent years, IL-17 A has been found to promote tissue fibrosis in many diseases. This article mainly analyzes the role of IL-17 A in related diseases from the perspective of inflammation and fibrosis, suggesting that using IL-17 A as an intervention target may benefit patients.
作者 芮奎 温冬梅 余思源 欧阳瑶 顾延会 RUI Kui;WEN Dong-mei;YU Si-yuan;OUYANG Yao;GU Yan-hui(First Department of Respiratory,the Affiliated Hospital of Zunyi Medical University,Zunyi 563000,Guizhou,CHINA)
出处 《海南医学》 CAS 2020年第10期1309-1312,共4页 Hainan Medical Journal
基金 国家自然科学基金(编号:81460008) 贵州省遵义市科学技术局项目[编号:遵市科合社字(2018)]。
关键词 白细胞介素-17A 炎症 细胞因子 纤维化 慢性阻塞性肺疾病 肺纤维化 肝硬化 系统性硬化症 Interleukin-17A(IL-17A) Inflammation Cytokine Fibrosis Chronic obstructive pulmonary disease Pulmonary fibrosis Hepatocirrhosis Systemic sclerosis
  • 相关文献

参考文献5

二级参考文献40

  • 1魏东,陈文慧.羟脯氨酸含量的测定方法优化[J].现代中西医结合杂志,2005,14(18):2479-2480. 被引量:11
  • 2Steen VD,Medsger TA.Changes in causes of death in systemicsclerosis,1972-2002[J].Ann Rheum Dis,2007,66(7):940-944.
  • 3Fenoglio D,Battaglia F,Parodi A,et al.Alteration of Th17 andTreg cell subpopulations co-exist in patients affected with systemicsclerosis[J].Clin Immunol,2011,139(3):249-257.
  • 4Ishikawa H,Takeda K,Okamoto A,et al.Induction of autoimmu-nity in a bleomycin-induced murine model of experimental systemicsclerosis:an important role for CD4+T cells[J].J Invest Der-matol,2009,129(7):1688-1695.
  • 5Yamamoto T.The bleomycin-induced scleroderma model:whathave we learned for scleroderma pathogenesis?[J].Arch Derma-tol Res,2006,297(8):333-344.
  • 6Zhang Y,McCormick LL,Desai SR,et al.Murine scleroderma-tous graft-versus-host disease,a model for human scleroderma:cutaneous cytokines,chemokines,and immune cell activation[J].J Immunol,2002,168(6):3088-3098.
  • 7D’hulst AI,Vermaelen KY,Brusselle GG,et al.Time course ofcigarette smoke-induced pulmonary inflammation in mice[J].EurRespir J,2005,26(2):204-213.
  • 8Yamamoto T,Takagawa S,Katayama I,et al.Effect of superoxidedismutase on bleomycin-induced dermal sclerosis:implications forthe treatment of systemic sclerosis[J].J Invest Dermatol,1999,113(5):843-847.
  • 9Fineschi S,Bongiovanni M,Donati Y,et al.In vivo investigations onanti-fibrotic potential of proteasome inhibition in lung and skin fibrosis[J].Am J Respir Cell Mol Biol,2008,39(4):458-465.
  • 10Ashcroft T,Simpson JM,Timbrell V.Simple method of estimatingseverity of pulmonary fibrosis on a numerical scale[J].J ClinPathol,1988,41(4):467-470.

共引文献35

同被引文献36

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部